Evidence map›Paper›PMID 39459532›Full record

ArticleLife (Basel, Switzerland)2024

Mortality Impact of Severe COVID-19 in the ICU: A Study from the Târgu Mureș Support Unit.

Janos Szederjesi, Irina Săplăcan, Marius Petrișor, Alexandra-Maria Șerdean, Bianca-Liana Grigorescu

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Janos SzederjesiDepartment of Intensive Care, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Târgu-Mureș, Romania.ORCID 0000-0001-9359-6058
Irina SăplăcanDepartment of Intensive Care, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Târgu-Mureș, Romania.
Marius PetrișorDepartment of Simulation Applied in Medicine, University of Medicine, Pharmacology, Science and Technology, 540139 Târgu-Mureș, Romania.
Alexandra-Maria ȘerdeanDepartment of Intensive Care, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Târgu-Mureș, Romania.
Bianca-Liana GrigorescuDepartment of Intensive Care, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Târgu-Mureș, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Since the onset of the COVID-19 pandemic, it has been recognized that a considerable proportion of critically ill patients may die of this disease. The current study aims to assess the overall 1-year outcomes within the UMFST COVID-19 Unit, providing valuable insights into the efficacy of specialized care facilities in managing severe cases of COVID-19. (2) Methods: This is a retrospective monocentric observational study including 294 patients confirmed to have SARS-CoV-2 infection. Demographic data and clinical and paraclinical parameters were assessed. Survival probabilities were estimated using Kaplan-Meier curves. (3) Results: Overall, the 1-year mortality was 89.4%. All deaths occurred in-hospital, with two patients dying after 28 days. Diabetes mellitus, chronic kidney failure, cerebrovascular disease, and atrial fibrillation were more prevalent in deceased patients. Thirty percent of patients needed endotracheal intubation during the first 24 h. The incidence of hospital-acquired pneumonia was higher among deceased patients. The SOFA score was significantly different between deceased vs. survivors. The survival analysis showed that the use of noradrenaline increased the likelihood of surviving COVID-19. (4) Conclusions: The severe comorbidities of the patients were the primary factors contributing to the increased mortality rate in the COVID-19 unit.

Indexed as

COVID19mortalitySARS-CoV-2

Identifiers

PMID39459532
PMCPMC11508922

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.